Considering the fact that the majority of CMT subtypes are due to mutations in myelin genes, collectively, our studies indicate that NT-3 gene therapy is well positioned with the potential to provide disease-modifying effects for the largest CMT patient population. This evidence concerns the gene NTF3 and Charcot-Marie-Tooth disease.